249 related articles for article (PubMed ID: 37053013)
21. Lethal persistent pulmonary hypertension of the newborn in Bohring-Opitz syndrome.
Kibe M; Ibara S; Inagaki H; Kato T; Kurahashi H; Ikeda T
Am J Med Genet A; 2018 May; 176(5):1245-1248. PubMed ID: 29681105
[TBL] [Abstract][Full Text] [Related]
22. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
[TBL] [Abstract][Full Text] [Related]
23. Bohring-Opitz syndrome caused by a novel ASXL1 mutation (c.3762delT) in an IVF baby: A case report.
Wang D; Yuan X; Guo H; Yan S; Wang G; Wang Y; Wang T; He J; Peng X
Medicine (Baltimore); 2022 Feb; 101(5):e28759. PubMed ID: 35119035
[TBL] [Abstract][Full Text] [Related]
24. Novel splicing mutation in the ASXL3 gene causing Bainbridge-Ropers syndrome.
Hori I; Miya F; Ohashi K; Negishi Y; Hattori A; Ando N; Okamoto N; Kato M; Tsunoda T; Yamasaki M; Kanemura Y; Kosaki K; Saitoh S
Am J Med Genet A; 2016 Jul; 170(7):1863-7. PubMed ID: 27075689
[TBL] [Abstract][Full Text] [Related]
25. De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome.
Bainbridge MN; Hu H; Muzny DM; Musante L; Lupski JR; Graham BH; Chen W; Gripp KW; Jenny K; Wienker TF; Yang Y; Sutton VR; Gibbs RA; Ropers HH
Genome Med; 2013; 5(2):11. PubMed ID: 23383720
[TBL] [Abstract][Full Text] [Related]
26. Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3).
Ayoub MC; Anderson JT; Russell BE; Wilson RB
Front Neurosci; 2023; 17():1244176. PubMed ID: 38027485
[TBL] [Abstract][Full Text] [Related]
27. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
[TBL] [Abstract][Full Text] [Related]
28. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
[TBL] [Abstract][Full Text] [Related]
29. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
Zhang P; He F; Bai J; Yamamoto S; Chen S; Zhang L; Sheng M; Zhang L; Guo Y; Man N; Yang H; Wang S; Cheng T; Nimer SD; Zhou Y; Xu M; Wang QF; Yang FC
J Clin Invest; 2018 Dec; 128(12):5383-5398. PubMed ID: 30226831
[TBL] [Abstract][Full Text] [Related]
30. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
[TBL] [Abstract][Full Text] [Related]
31. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
Inoue D; Kitaura J; Togami K; Nishimura K; Enomoto Y; Uchida T; Kagiyama Y; Kawabata KC; Nakahara F; Izawa K; Oki T; Maehara A; Isobe M; Tsuchiya A; Harada Y; Harada H; Ochiya T; Aburatani H; Kimura H; Thol F; Heuser M; Levine RL; Abdel-Wahab O; Kitamura T
J Clin Invest; 2013 Nov; 123(11):4627-40. PubMed ID: 24216483
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation.
Wu ZJ; Zhao X; Banaszak LG; Gutierrez-Rodrigues F; Keyvanfar K; Gao SG; Quinones Raffo D; Kajigaya S; Young NS
Int J Oncol; 2018 Apr; 52(4):1209-1223. PubMed ID: 29532865
[TBL] [Abstract][Full Text] [Related]
33. Further expanding the clinical phenotype in Bainbridge-Ropers syndrome and dissecting genotype-phenotype correlation in the ASXL3 mutational cluster regions.
Yu KP; Luk HM; Fung JLF; Chung BH; Lo IF
Eur J Med Genet; 2021 Jan; 64(1):104107. PubMed ID: 33242595
[TBL] [Abstract][Full Text] [Related]
34. Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature.
Cuddapah VA; Dubbs HA; Adang L; Kugler SL; McCormick EM; Zolkipli-Cunningham Z; Ortiz-González XR; McCormack S; Zackai E; Licht DJ; Falk MJ; Marsh ED
Am J Med Genet A; 2021 Jun; 185(6):1700-1711. PubMed ID: 33751773
[TBL] [Abstract][Full Text] [Related]
35. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
36. A novel de-novo frameshift mutation of the ASXL1 gene in a classic case of Bohring-Opitz syndrome.
Arunachal G; Danda S; Omprakash S; Kumar S
Clin Dysmorphol; 2016 Jul; 25(3):101-5. PubMed ID: 27043953
[No Abstract] [Full Text] [Related]
37. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC; Agosto-Peña J
Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
[TBL] [Abstract][Full Text] [Related]
39. De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome.
Srivastava A; Ritesh KC; Tsan YC; Liao R; Su F; Cao X; Hannibal MC; Keegan CE; Chinnaiyan AM; Martin DM; Bielas SL
Hum Mol Genet; 2016 Feb; 25(3):597-608. PubMed ID: 26647312
[TBL] [Abstract][Full Text] [Related]
40. The role of ASXL1 mutations and ASXL1 CircRNAs in cancer.
Jafarbeik-Iravani N; Kolahdozan S; Esmaeili R
Biomarkers; 2024 Feb; 29(1):1-6. PubMed ID: 38193494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
